logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9216180 B1

PDFFull Text
Date of Patent:
Dec. 22, 2015

Filed:

Oct. 02, 2013

Pharmaceutical compositions and treatment of genetic diseases associated with nonsense mediated rna decay

Applicants:

Lawrence B. Gardner, New York, NY (US);

Timothy J. Cardozo, New York, NY (US);

Leenus Martin, Harrison, NJ (US);

Inventors:

Lawrence B. Gardner, New York, NY (US);

Timothy J. Cardozo, New York, NY (US);

Leenus Martin, Harrison, NJ (US);

Assignee:

New York University, New York, NY (US);

Attorney:

LeClairRyan, a Professional Corporation

Primary Examiner:

My-Chau T Tran

Int. Cl.
CPC ...
A61K 31/535 (2006.01); A61K 31/415 (2006.01); A61K 31/505 (2006.01); A61K 31/53 (2006.01); A61K 31/4152 (2006.01); A61K 45/06 (2006.01); G01N 33/50 (2006.01); G06F 19/12 (2011.01); A61K 31/167 (2006.01); A61K 31/34 (2006.01); A61K 31/381 (2006.01); A61K 31/4035 (2006.01); A61K 31/4184 (2006.01); A61K 31/4192 (2006.01); A61K 31/433 (2006.01); A61K 31/445 (2006.01); A61K 31/513 (2006.01); A61K 31/538 (2006.01); G06F 19/16 (2011.01); G06F 19/00 (2011.01);
U.S. Cl.
CPC ...
A61K 31/53 (2013.01); A61K 31/167 (2013.01); A61K 31/34 (2013.01); A61K 31/381 (2013.01); A61K 31/4035 (2013.01); A61K 31/4152 (2013.01); A61K 31/4184 (2013.01); A61K 31/4192 (2013.01); A61K 31/433 (2013.01); A61K 31/445 (2013.01); A61K 31/513 (2013.01); A61K 31/538 (2013.01); A61K 45/06 (2013.01); G01N 33/5023 (2013.01); G06F 19/12 (2013.01); G06F 19/16 (2013.01); G06F 19/706 (2013.01);
Abstract

The present invention relates to pharmaceutical compositions comprising a compound and a pharmaceutically acceptable carrier. The present invention is also directed to a method of treating a genetic disease caused by premature termination codons, or other conditions that render messenger ribonucleic acid (mRNA) susceptible to nonsense mediated RNA decay, in a subject. Also disclosed is a method of inhibiting nonsense mediated RNA decay and/or induction of autophagy. The present invention also relates to a method of identifying inhibitors of nonsense mediated RNA decay and/or inducing autophagy. The present invention further relates to a method of inhibiting nonsense mediated RNA decay and/or induction of autophagy in a subject.

Find Patent Forward Citations

Loading…